Speeding up drug discovery for brain diseases
Whitehead Institute team finds drugs that activate a key brain gene; initial tests in cells and mice show promise for rare, untreatable neurodevelopmental disorder.
Whitehead Institute team finds drugs that activate a key brain gene; initial tests in cells and mice show promise for rare, untreatable neurodevelopmental disorder.
The new system, dubbed RESCUE, allows RNA edits to be made that were not previously possible.
By introducing a gene variant associated with autism into monkeys, researchers hope to study treatment options for severe neurodevelopmental disorders.
Researchers identify and develop new CRISPR-associated transposase system for targeted integration of DNA, adding key capabilities to gene-editing technology.
Researchers are developing a so-called "daisy-chain" gene-drive system that provides controls for genetic engineering of certain populations.
Rights are protected for broad use in developing world and for public health needs.
CRISPR team harnesses new Cas12b enzyme for use in eukaryotic cells, adding to the CRISPR toolbox.
Enzyme can target almost half of the genome’s “ZIP codes” and could enable editing of many more disease-specific mutations.
McGovern Institute scientist is recognized with award for outstanding and creative achievements made in the life and medical sciences.
Whitehead team deploys CRISPR tools to better understand and uncover ways of improving methotrexate, a popular chemotherapy drug.
A new daughter helped Alejandra Falla PhD ’18 gain perspective on life — and her tiny MIT regalia stole the show at Commencement.
Study reveals why people with the APOE4 gene have higher risk of the disease.
With SHERLOCK, a strip of paper can now indicate presence of pathogens, tumor DNA, or any genetic signature of interest.
Whitehead Institute researchers are using a modified CRISPR/Cas9-guided activation strategy to investigate the most frequent cause of intellectual disability in males.
Department of Biology kicks off IAP seminar series with a lecture by synthetic-biology visionary George Church.